Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises

ARS Pharmaceuticals Inc. reported better-than-expected earnings for the fourth quarter of 2025, with an EPS of -$0.41, surpassing the forecast of -$0.4246. Revenue also exceeded expectations, reaching $28.1 million against a forecast of $26.9 million. These results triggered a premarket stock price increase of 1.66%, bringing the share price to $9.21. The company maintains a market capitalization of $898.64 million and delivered a gross profit margin of 60% for the last twelve months.